Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Univ. Lab, Company Broaden Bacterial Vaccine Impact

Researchers from University at Buffalo and a campus spin-off enterprise devised a way to expand the scope of anti-bacterial vaccines, as shown in tests with lab animals. . . . → Read More: Univ. Lab, Company Broaden Bacterial Vaccine Impact

Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal

Drug maker Eli Lilly and Company and biotechnology company CureVac AG agreed to develop a series of cancer immunotherapies based on CureVac’s messenger RNA technology. . . . → Read More: Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal

Univ. Spin-Off Reports Cancer Immunotherapy Advance

A highly targeted synthetic antibody, developed by a university spin-off enterprise, was shown to destroy human breast cancer cells grafted in lab mice. . . . → Read More: Univ. Spin-Off Reports Cancer Immunotherapy Advance

Roche, Biotech to Discover New Antibiotics

A biotechnology company that discovers new drugs through detailed genomic analysis is partnering with drug maker Roche to find new treatments for bacterial infections that resist current antibiotics. . . . → Read More: Roche, Biotech to Discover New Antibiotics

Biotech Licenses Gene Editing for Autoimmune Disorders

A company developing therapies with gene editing technologies is acquiring a new form of gene editing on T-cells in the immune system to treat autoimmune diseases. . . . → Read More: Biotech Licenses Gene Editing for Autoimmune Disorders

Geisinger, Pharmas Partner on Diabetes Model

An alliance between the Geisinger Health System and two pharmaceutical companies is developing a computer model to predict long-term health risks of patients with type 2 diabetes. . . . → Read More: Geisinger, Pharmas Partner on Diabetes Model

Neuro Disease Start-Up Gains $30M in Early Funds

A start-up enterprise developing treatments for several neurological diseases that the company says are triggered by a common destructive protein, is raising $30 million its first venture financing round. . . . → Read More: Neuro Disease Start-Up Gains $30M in Early Funds

Drug Delivery Technology Licensed in $2B Deals

The biotechnology company Halozyme Therapeutics Inc. is licensing its technology for making infusion drugs deliverable with injections to two more drug makers. . . . → Read More: Drug Delivery Technology Licensed in $2B Deals

Trial Shows Antibody Effective Against Asthma

Results from a large-scale clinical trial show a synthetic antibody, when added to standard treatments, reduces asthma attacks and improves lung functioning. . . . → Read More: Trial Shows Antibody Effective Against Asthma

Trial Underway Testing Alzheimer’s-Schizophrenia Drug

A new clinical trial began in the U.K. in a test of an experimental drug to treat schizophrenia associated with Alzheimer’s disease. . . . → Read More: Trial Underway Testing Alzheimer’s-Schizophrenia Drug